Navigation Links
Nottingham leads £2.6m international clinical trial into new stroke treatment
Date:3/18/2013

Scientists in Nottingham are leading an international study to investigate the effectiveness of a new treatment on a devastating type of stroke.

The team at The University of Nottingham has been awarded 2.6 million by the National Institute for Health Research Health Technology Assessment (NIHR HTA) Programme to lead the clinical trial into the use of the drug tranexamic acid in people who have suffered an intracerebral haemorrhage, a type of stroke caused by bleeding in the brain.

Leading the trial, Dr Nikola Sprigg in the University's Division of Stroke, said: "This is potentially very exciting this drug could offer new hope for a condition for which there is currently no effective treatment.

"If successful, it could potentially improve the lives of thousands of people with haemorrhagic stroke, preventing deaths and reducing disability to increase their chances of leading a full and independent life."

Around 150,000 people in the UK suffer a stroke every year the majority of these are ischaemic strokes caused by a blocked blood vessel on the brain which can be treated very successfully in many cases with the use of clot-busting drugs (thrombolysis) administered within 4.5 hours of the stroke.

However, 15 per cent of all strokes affecting around 22,000 people every year are caused by haemorrhagic stroke when a blood vessel in the brain bursts, leading to permanent damage. Whilst all people with acute stroke benefit from treatment on a stroke unit, there is currently no specific treatment for haemorrhagic stroke and unfortunately many people affected will die within a few days. Those who do survive are often left with debilitating disabilities including paralysis and an inability to speak.

The four-year study will recruit around 2,000 people from 120 hospitals and stroke units, initially across the UK and then worldwide these will be people who come into hospital as an emergency after suffering from a suspected stroke.

It follows a small pilot study last year, funded by The University of Nottingham and charity the Stroke Association, which concluded that a larger study was needed to accurately assess the effectiveness of the drug tranexamic acid. The drug was chosen for the study after previous research showed that it was successful in stopping bleeding in people involved in road traffic accidents.

For the latest trial, people who are diagnosed as having had bleeding on the brain confirmed by CT scan will be offered the chance to take part in the study. Where the person is too ill to decide, permission will be asked of their family.

Half of those who sign up will be given the drug within eight hours of their stroke while half will receive a placebo. The patient's progress will be carefully monitored in hospital over the course of the next seven days and they will receive a second CT scan to see whether the amount of blood on the brain has increased.

The study team will then follow up with the person after three months to assess their recovery, level of disability and how independent they are following their stroke.

The rationale behind giving the treatment so quickly (less than eight hours after stroke onset), is in an attempt to reduce the risk of continued bleeding, therefore potentially reducing the amount of permanent brain damage caused.

The Division of Stroke and Nottingham Stroke Trials Unit, based at Nottingham University Hospitals NHS Trust's City Hospital campus, has an international reputation for clinical and laboratory research in stroke. It also works closely with NHS colleagues in running the nationally-acclaimed clinical stroke service at the hospital.

Recruitment starts this week, initially at 30 UK centres including Nottingham, with further centres across the UK and worldwide expected to join the study in coming months.


'/>"/>

Contact: Emma Thorne
emma.thorne@nottingham.ac.uk
44-011-595-15793
University of Nottingham
Source:Eurekalert

Related medicine news :

1. Nottingham expertise in major European drug discovery partnership
2. Research leads to better understanding of peripheral neuropathy
3. Manchester leads new international study investigating Inflammatory Bowl Disease
4. Premium Astrology Client Care Team Leads Norah Guide to New Reviews Daily
5. Inhaled betadine leads to rare complication
6. Platypus Australia Leads The Way For Summer Fashion By Launching New Range of Children’s UV Protective Swimwear
7. Frog-in-bucket-of-milk folklore leads to potential new antibiotics
8. University of Cincinnati leads first trial on steroid and CNI withdrawal post-transplant
9. Decreased kidney function leads to decreased cognitive functioning
10. Childhood abuse leads to poor adult health
11. Healthy outlook leads to a healthy lifestyle: study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their media with ... X," said Christina Austin - CEO of Pixel Film Studios. , ProSlice Color ... users can now reveal the media of their split screens with growing colorful ...
(Date:6/27/2016)... ... 2016 , ... A revolution is underway. Brooklyn-based company, ... for the millions of people who require these medical transport services annually. ... the use of technology. Now, SmartEMS has put forth an industry-changing app that ...
(Date:6/26/2016)... ... 2016 , ... On June 10-11, 2016, A Forever Recovery, a holistic treatment ... Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility is located. This ... of the world’s leading providers of cereal and other breakfast foods. Its residents often ...
(Date:6/26/2016)... ... ... blind and certified personal trainer is helping to develop a weight loss fitness plan that ... the two major problems leading the fitness industry today:, , All ... They don’t eliminate all the reasons people quit their exercise program , ...
(Date:6/25/2016)... ... 25, 2016 , ... Austin residents seeking Mohs surgery services, can now turn ... to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization ... selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it ... (procalcitonin) assay as a dedicated testing solution for people ... Roche is the first IVD company in the U.S ... assessment and management. PCT is a sepsis-specific ... blood can aid clinicians in assessing the risk of ...
(Date:6/23/2016)... Bracket , a leading clinical trial technology ... outcomes platform, Bracket eCOA (SM) 6.0, at the 52 ... 30, 2016 in Philadelphia , Pennsylvania.  A ... product of its kind to fully integrate with RTSM, will ... 6.0 is a flexible platform for electronic clinical outcomes assessments ...
(Date:6/23/2016)... LONDON , June 23, 2016 ... environments  Oticon , industry leaders in ... the launch of Oticon Opn ™, the world,s ... world of possibilities for IoT devices.      ... Opn, Oticon introduces a number of ,world firsts,: ...
Breaking Medicine Technology: